Enzon's Losses Mount Amid Zero Revenue, Viskase Merger Costs

Ticker: ENZN · Form: 10-Q · Filed: Nov 12, 2025 · CIK: 727510

Sentiment: bearish

Topics: Pharmaceuticals, Mergers and Acquisitions, Biotech, Financial Performance, SEC Filings, Cash Burn, Strategic Outlook

Related Tickers: ENZN, VKS

TL;DR

**ENZN is a cash-burning shell company whose future is entirely dependent on a risky merger with Viskase, making it a speculative bet at best.**

AI Summary

Enzon Pharmaceuticals, Inc. (ENZN) reported a net loss of $824,000 for the three months ended September 30, 2025, a significant increase from the net income of $254,000 in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $2.338 million, compared to a net income of $850,000 in the prior year. Total revenues remained at $0 for both the three and nine months ended September 30, 2025, down from $26,000 in the nine months ended September 30, 2024. Operating expenses surged to $1.304 million for the quarter and $3.839 million for the nine-month period in 2025, primarily due to $1.075 million in transaction expenses for the quarter and $2.801 million for the nine months related to the planned merger with Viskase Companies, Inc. Cash and cash equivalents decreased to $43.256 million as of September 30, 2025, from $46.859 million at December 31, 2024. The company's strategic outlook is centered on becoming an acquisition platform, with a definitive merger agreement with Viskase Companies, Inc. signed on June 20, 2025, and amended on October 24, 2025. Risks include the uncertainty of future royalty payments, as historical licensing agreements have yielded minimal or no revenue, and the successful completion of the Viskase merger.

Why It Matters

Enzon's continued lack of revenue and increasing operating losses, driven by transaction expenses for the Viskase merger, signal a critical juncture for investors. The company's pivot to an 'acquisition vehicle' means its future hinges entirely on the successful integration and performance of Viskase, a significant competitive shift from its historical pharmaceutical licensing model. For employees, the merger could bring changes in corporate structure and roles. Customers of Viskase, if the merger proceeds, might see changes in product offerings or service, while the broader market will watch if this 'acquisition platform' strategy can revive a company with a decade of limited operations. The competitive landscape for ENZN is now defined by its ability to execute this merger and leverage Viskase's existing business.

Risk Assessment

Risk Level: high — The risk level is high due to zero revenue reported for the three and nine months ended September 30, 2025, and a net loss of $2.338 million for the nine-month period. The company's strategy is entirely dependent on the successful completion of a merger with Viskase Companies, Inc., which introduces significant execution risk and has already incurred $2.801 million in transaction expenses.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the progress of the Viskase merger closely, as its success or failure will dictate ENZN's future. Given the lack of current revenue and increasing losses, a 'wait and see' approach is advisable until the merger is finalized and the combined entity's financial prospects become clearer.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
$43.693M
total Debt
$0.540M
net Income
$(2.338)M
eps
$(0.05)
gross Margin
N/A
cash Position
$43.256M
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Royalties and milestones, net$0N/A

Key Numbers

Key Players & Entities

FAQ

What were Enzon Pharmaceuticals' revenues for the quarter ended September 30, 2025?

Enzon Pharmaceuticals, Inc. reported zero revenue for the three months ended September 30, 2025, and also for the nine months ended September 30, 2025. This is a decrease from $26,000 in royalties and milestones for the nine months ended September 30, 2024.

What was Enzon's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Enzon Pharmaceuticals, Inc. reported a net loss of $2.338 million. This compares to a net income of $850,000 for the same period in 2024.

What is the primary strategic focus for Enzon Pharmaceuticals, Inc.?

Enzon Pharmaceuticals, Inc. is positioned as a public company acquisition vehicle, with its primary strategic focus being to become an acquisition platform. This strategy is currently centered on a planned merger with Viskase Companies, Inc., as per an agreement signed on June 20, 2025.

How much cash and cash equivalents did Enzon Pharmaceuticals have as of September 30, 2025?

As of September 30, 2025, Enzon Pharmaceuticals, Inc. had $43.256 million in cash and cash equivalents. This represents a decrease from $46.859 million reported at December 31, 2024.

What are the main risks highlighted in Enzon's 10-Q filing?

Key risks include the uncertainty of receiving any future royalties or milestone payments, as historical licensing agreements have yielded minimal revenue for over ten years. Additionally, the company's future is heavily reliant on the successful completion of the merger with Viskase Companies, Inc., which is not assured.

How have transaction expenses impacted Enzon's financial results?

Transaction expenses significantly impacted Enzon's operating expenses, totaling $1.075 million for the three months and $2.801 million for the nine months ended September 30, 2025. These costs are primarily related to the planned merger with Viskase Companies, Inc. and contributed to the increased operating loss.

What is the status of Enzon's merger agreement with Viskase Companies, Inc.?

Enzon Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Viskase Companies, Inc. on June 20, 2025, which was amended on October 24, 2025. Enzon plans to merge its wholly owned subsidiary, EPSC Acquisition Corp., with and into Viskase.

Does Enzon Pharmaceuticals expect to receive future royalty payments?

Enzon Pharmaceuticals cannot assure that it will receive any future royalties or milestone payments. Historically, the company has received only minimal payments on its licenses in the last two years, and a marketing agreement for Vicineum was canceled.

What is Enzon's accumulated deficit as of September 30, 2025?

As of September 30, 2025, Enzon Pharmaceuticals, Inc. reported an accumulated deficit of $72.230 million. This has increased from an accumulated deficit of $69.892 million at December 31, 2024.

What is the significance of Enzon's net operating loss carryforwards?

Enzon Pharmaceuticals, Inc. had federal net operating loss carryforwards (NOLs) of approximately $101 million as of September 30, 2025. These NOLs could potentially offset future taxable income, with $97.8 million expiring between 2025 and 2036, and the remainder having an unlimited carryforward period under the Tax Cuts and Jobs Act.

Risk Factors

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often pursue mergers and acquisitions to gain access to new technologies, expand product pipelines, or achieve economies of scale. Enzon's strategy to become an acquisition platform aligns with this trend, aiming to leverage its existing structure and potential tax assets.

Regulatory Implications

As a pharmaceutical company, Enzon is subject to stringent regulations from bodies like the FDA. While current operations appear minimal, any future product development or acquisition would necessitate adherence to these complex regulatory frameworks. The Viskase merger may also involve regulatory reviews depending on the nature of Viskase's business.

What Investors Should Do

  1. Monitor Viskase Merger Progress
  2. Assess Post-Merger Viability
  3. Evaluate Cash Burn Rate

Key Dates

Glossary

Mezzanine equity
A hybrid form of financing that blends debt and equity features. In this case, it refers to Series C preferred stock. (Represents a significant portion of the company's capital structure ($44.076 million as of September 30, 2025) and impacts the equity available to common shareholders.)
Accumulated deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Enzon has an accumulated deficit of $72.230 million as of September 30, 2025, reflecting its history of net losses.)
Transaction expenses
Costs incurred by a company in connection with mergers, acquisitions, or other significant corporate transactions. (These expenses ($2.801 million for the nine months ended September 30, 2025) are a primary driver of the company's current operating losses and are directly related to the Viskase merger.)
Federal NOL Carryforwards
Net Operating Loss (NOL) carryforwards represent past operating losses that can be used to offset future taxable income, reducing tax liabilities. (While not explicitly detailed in the provided text, the mention of $101M in Federal NOL Carryforwards suggests a potential future tax benefit if the company achieves profitability, especially post-merger.)

Year-Over-Year Comparison

Enzon Pharmaceuticals has experienced a significant financial downturn compared to the prior year. Total revenues have dropped to $0 from $26,000 for the nine-month period, leading to a shift from net income of $850,000 to a net loss of $2.338 million for the first nine months of 2025. Operating expenses have surged due to $2.801 million in transaction expenses related to the Viskase merger, a cost not present in the prior year. Consequently, the company's cash position has decreased from $46.859 million at year-end 2024 to $43.256 million as of September 30, 2025.

Filing Stats: 4,667 words · 19 min read · ~16 pages · Grade level 14.6 · Accepted 2025-11-12 16:22:28

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21

– OTHER INFORMATION

PART II – OTHER INFORMATION 21 Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

Signatures

Signatures 27 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) September 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 43,256 $ 46,859 Other current assets 411 293 Total current assets 43,667 47,152 Deferred tax asset 26 17 Total assets $ 43,693 $ 47,169 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities: Accounts payable $ 331 $ 331 Accrued expenses and other current liabilities 209 72 Dividends payable on Series C preferred stock — 1,275 Total current liabilities 540 1,678 Commitments and contingencies Mezzanine equity: Series C preferred stock - $ 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value $ 1,102 and $ 1,062 per share) at September 30, 2025 and December 31, 2024 44,076 42,483 Stockholders' (deficit) equity: Preferred stock - $ 0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock - $ 0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at September 30, 2025 and December 31, 2024 742 742 Additional paid-in capital 70,565 72,158 Accumulated deficit ( 72,230 ) ( 69,892 ) Total stockholders' (deficit) equity ( 923 ) 3,008 Total liabilities, mezzanine equity and stockholders' (deficit) equity $ 43,693 $ 47,169 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Revenues: Royalties and milestones, net

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing